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Background and PurposezzFrovatriptan is a selective 5-HT1B/1D agonist with a long duration 
of action and a low incidence of side effects. Although several placebo-controlled trials have 
documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has 
not previously been studied in Asian including Korean patients.
MethodszzIn this double-blind multicenter trial, 229 patients with migraine were randomized 
to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. 
The primary outcome was the 2-hour headache response rate.
ResultszzFrovatriptan significantly increased the 2-hour headache response rate compared with 
placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were signifi-
cantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2 
hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%, 
p=0.002). The median time to a headache response was significantly shorter in the frovatriptan 
group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications 
was more common in the placebo group (p=0.005). Chest tightness associated with triptan was in-
frequent (2.5%), mild, and transient.
ConclusionszzThese results demonstrate that 2.5-mg frovatriptan is effective and well tolerat-
ed in Korean migraineurs for acute treatment of migraine attacks.     J Clin Neurol 2010;6:27-32
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Introduction
Sumatriptan, the first commercially available triptan drug, 
has had a significant clinical impact on the acute treatment of 
migraine. Although used for decades as a standard treatment 
for acute migraine, sumatriptan has several limitations, in-
cluding unexpected low efficacy, recurrent headache caused 
by its short half-life, and intolerable adverse effects (AEs).
1,2 
The newer triptans, including frovatriptan, were developed 
to improve the clinical efficacy and reduce AEs. Compared 
with sumatriptan, frovatriptan has a fivefold greater affinity 
for serotonin 5-HT1B/1D receptors, a superior functional selec-
tivity for cerebral arteries than coronary arteries,
3 and an 
approximately tenfold longer half-life (25 hours),
4 suggesting 
that frovatriptan offers greater efficacy, a lower recurrence 
rate, and more tolerability than other 5-HT1B/1D agonists. Frovatriptan for Acute Migraine in Koreans
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Data regarding the efficacy and safety of triptans in Asian 
migraine patients are limited, but several clinical trials have 
shown that Asians exhibit different results for the mitochon-
drial polymorphism (A11084G), different pharmacokinetics 
and pharmacodynamic profiles, greater placebo effects, and 
higher incidences of AEs than Caucasian patients.
5-9 These 
findings indicate that the relatively low preference for trip-
tans in Asian populations may be partially related to their 
relative sensitivity to the AEs of these drugs. 
Frovatriptan has been shown to be effective in the acute 
management of migraine
4,10,11 and in the management of men-
strual migraine.
12 However, all previous trials of frovatriptan 
were conducted primarily in Western countries, with no sys-
tematic studies performed in Asian countries, including Ko-
rea. We therefore designed this clinical trial to assess the ef-
ficacy, tolerability, and safety of frovatriptan in Korean mig-
raine patients.
Methods
Study hypothesis and subjects 
The primary hypothesis was that frovatriptan would provide 
greater migraine relief than placebo. The secondary hypothe-
sis was that the AE profile of frovatriptan would be similar to 
that of placebo. 
Eligible patients were men and women, aged 18 to 65 years, 
with a history of migraine with or without aura for at least 12 
months, as defined by the International Classification of Head-
ache Disorders-II (ICHD-II) criteria.
13 All patients had expe-
rienced one to eight moderate-to-severe migraine episodes per 
month for at least two consecutive months prior to enrollment. 
Exclusion criteria were 1) a history of basilar, ophthalmo-
plegic, or hemiplegic migraine, 2) >15 headache days per mo-
nth prior to screening, 3) cerebrovascular, cardiac, hepatic, 
or renal disease, 4) being pregnant or breast-feeding, 5) a hi-
story or current evidence of drug or alcohol abuse, 6) a his-
tory of exposure to frovatriptan, 7) treatment with any other 
investigational compound or device within 30 days of the start 
of this study, and 8) initial onset of migraine after the age of 
50 years.
Study design and interventions 
This double-blind, placebo-controlled, randomized trial was 
conducted in eight headache centers in Korea from Novem-
ber 2006 to November 2007. All participating investigators 
were neurologists specializing in headache throughout Ko-
rea. This study protocol was reviewed and approved by the 
Korean Food and Drug Administration (FDA) and the insti-
tutional review board of each center. Each patient provided 
written informed consent prior to study entry. The study was 
supervised by the Korean FDA in accordance with the Dec-
laration of Helsinki and Good Clinical Practice guidelines. 
Treatments were allocated according to a predetermined 
computer-generated randomization program provided by 
Statistical Analysis System (SAS). Randomization was in a 1 
: 1 ratio of frovatriptan (2.5 mg) to placebo. The block size 
used was four or six. Eligible patients were assigned sequen-
tial randomization numbers upon study entry. Both participants 
and investigators were blinded to treatment assignment. 
After randomization, the patients were given the study med-
ication, rescue medication (ibuprofen), and a diary to record 
their migraine attacks. Within 12 weeks after randomization, 
patients were asked to take the study medication when they 
had a migraine attack of moderate-to-severe intensity and re-
cord each such attack in their diary. 
Rescue medication (200-mg ibuprofen) was permitted when 
patients suffered from sustained moderate-to-severe head-
ache for at least 2 hours after taking the study medication or 
suffered a recurrent migraine headache of moderate-to-se-
vere intensity within 24 hours. No other analgesics or antieme-
tics were allowed from 6 hours before to 2 hours after taking 
the study medication. Triptans or ergotamine-containing dru-
gs were also not allowed within 24 hours. Use of the study 
medication and rescue medication was recorded in the head-
ache diary. Within 48 hours of taking the study medication, 
patients were to contact their assigned investigators to re-
view the efficacy and AEs of the study medication. Follow-
up visits were scheduled within 5 days of the end of the study 
to allow the subjects to submit headache diaries and return 
unused medication. Patients who did not take the study medi-
cation within 12 weeks from randomization were not includ-
ed in the analysis. 
Assessments 
Patients recorded efficacy and tolerability data in their head-
ache diaries at baseline and at 2, 4, 6, 12, and 24 hours after 
taking the study medication. Headache severity was assessed 
according to the International Headache Society (IHS) 4- 
point rating scale, where 0=absent, 1=mild, 2=moderate, and 
3=severe. The primary efficacy outcome measure was the 
2-hour headache response rate, defined as the proportion of 
patients experiencing a change in headache intensity: from 
moderate or severe at baseline to mild or no pain at 2 hours. 
The secondary efficacy outcome measures were the head-
ache responses at 4, 6, 12, and 24 hours after taking the study 
medication, the proportion of patients who were pain free at 
2, 4, and 6 hours after taking the study medication, and the 
time to the first headache response of a mild headache or no 
headache. Headache recurrence was also evaluated, which 
was defined as the proportion of patients who had headache Moon HS et al.
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relief at 4 hours and whose headache returned to a moderate-
to-severe level within 24 hours. The proportion of patients 
who remained pain free at 24 hours and the use of rescue 
medication were also measured.
The safety and tolerability of frovatriptan were assessed 
by performing a full physical examination, laboratory assess-
ments, vital signs, and a 12-lead effect of continuous electrocar-
diography (ECG) examination. All AEs occurring between 
dosing and follow-up were recorded on patient diary cards. 
Statistical analyses
Sample size calculations were based on assumed treatment 
response rates of 27% for placebo and 46% for frovatriptan 
at the 5% significance level (two-sided) with 80% statistical 
power.
11,14 We calculated that 200 subjects were required, and 
so based on an estimated 20% dropout rate, we planned to 
recruit 250 subjects. All efficacy data were analyzed on a full 
analysis set (FAS), which included all patients who took the 
study medication and completed at least one efficacy evalua-
tion. Per protocol (PP) analysis was performed after exclud-
ing major protocol violators from the FAS population.
The observed data for each time point were used for analy-
sis. Data not recorded in patients’ diaries in a timely fashion 
were not included. 
Logistic regression analysis was applied to the 2-hour res-
ponse rate, and logistic regression models were used for the 
recurrence rate. The log-rank test was used to compare the 
time to a headache response and the time to recurrence be-
tween the two groups. All statistical tests had a two-sided 
significance level of 0.05. 
Results
Patient characteristics
A total of 298 patients were randomized to receive treatment 
with frovatriptan or placebo (Fig. 1). Of these, 229 patients 
who had taken the study medication at least once due to mi-
graine headache were included in the FAS analysis. 
As indicated in Table 1, the baseline characteristics of the 
participants did not differ significantly between the frovatrip-
tan and placebo groups. Most participants were women 
(90.39%), and about half (41.48%) had taken triptans for mi-
graine treatment. The baseline headache severity and the me-
dian interval between onset and treatment with the study 
medication also did not differ significantly between the two 
groups. 
 
Efficacy outcomes
As shown in Fig. 2, the primary endpoint (headache relief at 
2 hours after taking the study medication) was reported by 
64 of 121 evaluable patients (52.89%) in the frovatriptan 
group, compared with 36 of 106 patients (33.96%) in the 
placebo group (p=0.004). Frovatriptan also showed signifi-
cant superiority over placebo in almost all other outcome 
measures, including the headache responses at 4, 6, and 12 
hours after taking the study medication, the percentage who 
were pain free for up to 6 hours, sustained headache relief af-
ter becoming pain free, time to first headache response, and 
use of rescue medication (Table 2 and 3). Similar results were 
seen in the PP population.
Among 159 patients who achieved headache relief after 4 
Fig. 1. Subject disposition. FAS: full analysis 
set, PP: per protocol, ITT: intention-to-
treat.
Frovatriptan
Enrolled
Randomized
ITT, FAS
PP
Placebo
27 excluded
No chance to treat: 16
Inclusion violation: 4
Consent withdrawal: 6
Lose to follow-up: 0
Miscellaneous: 1
13 excluded
Major protocol violation: 13
149
122 107
109 95
298
149
12 excluded
Major protocol violation: 12
42 excluded
No chance to treat: 30
Inclusion violation: 7
Consent withdrawal: 4
Lose to follow-up: 1
Miscellaneous: 0Frovatriptan for Acute Migraine in Koreans
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hours, 29 experienced headache recurrence within 24 hours: 
16.13% (15/93) in the frovatriptan group and 21.21% (14/66) 
in the placebo group (p=0.41). Rescue medications were used 
more frequently in the placebo group than in the frovatriptan 
group (p=0.005), and they were usually taken between 2 and 
4 hours after taking the study medication; 55 of 73 patients 
(75.34%) took the rescue medication within this time period 
in the placebo group compared with 39 of 61 (63.93%) in the 
frovatriptan group. 
Safety and tolerability outcomes
The overall rate of AEs did not differ significantly between 
the frovatriptan group (38 AEs in 27 subjects; 22.13%) and 
the placebo group (26 AEs in 14 subjects; 13.08%) (p=0.07). 
All AEs were transient and had a mild-to-moderate intensity. 
The most common AE in the frovatriptan group was nausea 
(7.38%) (Table 4). In contrast, AEs associated with triptan 
symptoms, including chest tightness, were infrequent (2.46%), 
mild, and resolved without intervention. No clinically mean-
ingful changes in vital signs, laboratory values, or ECG out-
comes were observed. 
Discussion
This was the first randomized, double-blind, placebo-con-
trolled trial to evaluate the efficacy and tolerability of frovat-
riptan (2.5 mg) in Korean migraineurs. Frovatriptan was sig-
nificantly more effective in relieving migraine headaches 
compared with placebo. The headache response rate at 2 ho-
urs was 52.89% in the frovatriptan group, which is similar to 
the findings of earlier trials of frovatriptan.
11 The efficacy re-
sult in this study was similar to that found in a previous trial 
of zolmitriptan (2.5 mg) in Korean migraineurs, where the 
headache response rate at 2 hours was 52.2% in the zolmi-
triptan group and 30.7% in the placebo group.
15 We found 
Table 1. Demographic and baseline migraine characteristics of the intention-to-treat population
Frovatriptan (n=122) Placebo (n=107) p value
Age, mean (SD), years  36.75 (10.23) 38.07 (9.22)0 0.31
Females, n (%) 0.113 (92.62) 00.94 (87.85) 0.22
Age distribution, n (%) 
    <30 years 00.37 (30.33) 00.24 (22.43) 0.53
    30-39 years 00.37 (30.33) 00.34 (31.78)
    40-49 years 00.34 (27.87) 00.37 (34.58)
    >50 years 00.14 (11.48) 00.12 (11.21)
Migraine history at screening 
    Without aura, n (%)  0.100 (81.97) 00.87 (81.31) 0.83
    Mean duration of migraine history, mean (SD), years  7.50 (6.75) 08.33 (7.58)0 0.40
    Number of attacks per month, mean (SD)  3.54 (2.08) 3.33 (1.91) 0.44
    Patients who previously used triptans, n (%)  0.050 (40.98) 00.45 (42.06) 0.87
Migraine characteristics at baseline 
    Pain severity, n (%) 
        Moderate  0.094 (77.05) 00.88 (82.24) 0.33
        Severe  0.028 (22.95) 00.19 (17.76)
Median time between migraine onset and treatment, median
  (interquartile range), hours 
        1.38 (0.17-3.53)  00.   2.00 (0.42-5.33) 0.14 
Frovatriptan
p=0.0040
Placebo
60
(%)
50
40
30
20
10
0
2 h
Fig. 2. Proportion of subjects experiencing headache relief over 
time.
Table 2. Headache response rates in full analysis set analysis
Time after taking  
the study medication
Frovatriptan 
n/N (%)
Placebo 
n/N (%)
p value
02 hours 064/121 (52.89) 36/106 (33.96) 0.004
04 hours 093/113 (82.30) 66/100 (66.00) 0.007
06 hours 0092/98 (93.88) 071/94 (75.53)  <0.001
12 hours 0093/96 (96.88) 064/78 (82.05) 0.004
24 hours 107/117 (91.45) 87/102 (85.29) 0.160Moon HS et al.
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that the placebo-subtracted values of the headache response 
were maintained in about 20% of patients for up to 12 hours, 
which may be related to the long half-life of frovatriptan. 
Frovatriptan has the longest half-life among the triptans, 
and hence it can be expected to be associated with a low mi-
graine recurrence rate and a long duration of action. Previous 
trials of frovatriptan have found low 24-hour headache recur-
rence rates (7% to 19%).
7 In contrast, clinical trials of sumat-
riptan, zolmitriptan, and rizatriptan have all found 24-hour 
headache recurrence rates of around 30%.
16,17 In the present 
study, the 24-hour headache recurrence was lower in the 
frovatriptan group (16.13%) than in the placebo group (21.21 
%), but did not reach significance. A significantly higher pro-
portion of patients in the placebo group took additional anal-
gesics as rescue medications, which may have led to the re-
currence rate being an underestimated. More accurate data 
for the 24-hour headache recurrence requires prohibition of 
rescue medication during the first 24 hours. However, ethi-
cally it is difficult to restrict the use of rescue medications.
Overall, 41.48% of the patients in this trial had previously 
been exposed to triptans. This high proportion of previous 
triptan users may be attributed to our strict inclusion criteria, 
including a history of typical moderate-to-severe migraines 
of least 12 months. The efficacy of frovatriptan was mea-
sured as the headache response rate to single attacks, and the 
participants were expected to be sufficiently experienced in 
differentiating typical migraine attacks from other headache 
syndromes within 2 hours of headache onset. This did not ap-
pear to affect the efficacy and tolerability results because 
there were no differences between triptan-experienced and 
triptan-naïve patients. 
AEs were reported by 22.13% of patients in the frovatrip-
tan group, which is a lower percentage than in previous trials 
of frovatriptan,
10 and lower than in trials of sumatriptan (100 
mg) (39.0%)18 and naratriptan (2.5 mg) (38.31%)19 in Korean 
migraineurs. In particular, the incidence of chest tightness 
was 2.46% in the frovatriptan group, which is lower than re-
ported for other triptans, including sumatriptan,
20 zolmitrip-
tan,
21 and rizatriptan.
22 
Our efficacy outcomes and safety profiles were similar to 
those found in previous trials in Western countries. Because 
there is a paucity of data regarding the efficacy of triptans in 
Asian populations, previous such results may have been at-
tributed to racial differences. Unlike other Asian studies,
6,7,23 
we did not observe a high placebo effect that could have neg-
atively influenced the relative benefit of triptans. Our appli-
cation of strict inclusion criteria and the supervision of study 
coordinators in selecting migraine attack for study medica-
tion may have increased the clinical accuracy. Moreover, this 
study was ultimately subject to approval by the Korean FDA, 
and the results were stringently evaluated and monitored un-
der its supervision. 
This study had several limitations. First, the intraindividual 
response consistency could not be estimated because efficacy 
results were based on single doses for single migraine attacks. 
This limitation may not be problematic due to the consistent 
results observed among the participating centers and the 
finding of similar results in previous Western trials of frovat-
riptan. Second, interindividual variations could not be ac-
cessed because this study did not use a crossover design. 
In summary, this study demonstrated that frovatriptan (2.5 
mg) is a generally effective and well-tolerated treatment for 
Korean patients with moderate-to-severe migraine. 
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